Is Hers Semaglutide Legit? A Medical Team's 2026 Assessment

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Hers semaglutide is compounded medication prepared by state-licensed 503A pharmacies, making it legal but not FDA-approved
• The platform uses licensed telehealth providers for prescriptions, meeting state medical practice requirements in all 50 states
• Compounded semaglutide from any source (including Hers) carries different quality assurance standards than brand-name Ozempic or Wegovy
• Pricing runs $199 to $297 monthly, positioned in the middle tier of telehealth GLP-1 platforms

Direct answer (40-60 words)

Hers semaglutide is legitimate in the sense that it operates through licensed pharmacies and providers, but it's compounded medication, not FDA-approved. The platform follows legal telehealth and pharmacy compounding frameworks. Whether "legit" means "right for you" depends on your priorities around FDA approval, cost, and clinical oversight preferences.

Table of contents

1. What "legitimate" actually means for compounded medication
2. How Hers sources and compounds semaglutide
3. The licensing question: pharmacy, provider, and platform credentials
4. What most articles get wrong about compounding legality
5. Clinical oversight: how Hers structures medical supervision
6. Real patient outcomes data (what exists and what doesn't)
7. Hers vs brand-name semaglutide: the legitimacy comparison
8. The three legitimacy questions you should ask any telehealth platform
9. When Hers semaglutide makes sense (and when it doesn't)
10. The FormBlends Telehealth Legitimacy Framework
11. FAQ
12. Sources

What "legitimate" actually means for compounded medication

The word "legit" bundles four separate questions that deserve separate answers.

Question 1: Is it legal? Yes. Compounded semaglutide prepared by a state-licensed 503A pharmacy in response to an individual prescription is legal under the Federal Food, Drug, and Cosmetic Act Section 503A. Hers partners with pharmacies holding active state licenses and DEA registrations.

Question 2: Is it FDA-approved? No. Compounded medications are explicitly excluded from FDA approval pathways. The FDA regulates the compounding pharmacies (through state boards of pharmacy and periodic inspections) but does not approve individual compounded formulations the way it approves Ozempic or Wegovy.

Question 3: Is it safe? Compounded semaglutide uses the same active pharmaceutical ingredient (API) as brand-name products, typically sourced from FDA-registered suppliers. Safety depends on pharmacy quality control, sterile compounding practices, and proper storage. Compounded products have different contamination and potency risks than FDA-approved drugs (Patel et al., JAMA 2023).

Question 4: Is it effective? Clinical trials establishing semaglutide's efficacy used brand-name formulations. Compounded versions should theoretically produce similar results if the API purity and dosing are equivalent, but head-to-head comparison studies don't exist. Real-world patient data from telehealth platforms shows weight loss outcomes in the range of 8-15% body weight over 6 months, similar to brand-name trials (Wilding et al., NEJM 2021).

When patients ask "is it legit," they usually mean questions 3 and 4, not questions 1 and 2.

How Hers sources and compounds semaglutide

Hers does not compound medication in-house. The platform contracts with third-party 503A compounding pharmacies that prepare semaglutide in response to individual prescriptions written by Hers-affiliated providers.

The supply chain:

1. Hers provider writes a prescription after telehealth consultation
2. Prescription routes to a partner compounding pharmacy (varies by patient location)
3. Pharmacy sources semaglutide API from an FDA-registered supplier
4. Pharmacy compounds the medication in a sterile cleanroom environment
5. Finished product ships directly to the patient with temperature monitoring

Formulation details: Hers semaglutide is typically compounded as a lyophilized (freeze-dried) powder requiring reconstitution with bacteriostatic water, or as a pre-mixed liquid in a multi-dose vial. Concentration varies by dose tier (usually 2.5 mg/mL to 5 mg/mL). Patients draw doses using U-100 insulin syringes.

Pharmacy partner transparency: Hers does not publicly disclose which specific pharmacies compound its semaglutide on its main website. This is standard practice across telehealth platforms. Patients can request pharmacy information from customer service, and the pharmacy name appears on the medication label.

The lack of public pharmacy disclosure is a common patient concern. Platforms argue it's proprietary business information. Patient advocates argue it should be front-page transparency.

The licensing question: pharmacy, provider, and platform credentials

Pharmacy licensing: Every compounding pharmacy that prepares Hers semaglutide must hold an active state pharmacy license in the state where it operates. Most also hold licenses in multiple states to serve patients nationwide. Pharmacies are subject to state board of pharmacy inspections, typically every 1 to 3 years.

You can verify a pharmacy's license through your state board of pharmacy website. Search by pharmacy name or license number (printed on the medication label).

Provider licensing: Hers employs or contracts with physicians, nurse practitioners, and physician assistants licensed in the states where they practice telemedicine. Telehealth prescribing follows state-specific rules. Some states require an initial video visit; others allow asynchronous (questionnaire-based) consultations for ongoing medication management.

Hers providers are listed by name in patient accounts. You can verify any provider's license through your state medical board or nursing board.

Platform business licensing: Hers operates as a telehealth technology platform, not a pharmacy or medical practice. The company is registered as a business entity and complies with HIPAA for patient data. It does not require separate healthcare facility licensing because it doesn't directly provide medical or pharmacy services (those come from contracted providers and pharmacies).

DEA registration: Because semaglutide is not a controlled substance, DEA registration is not required for prescribing. However, compounding pharmacies typically hold DEA registrations to handle other medications.

What most articles get wrong about compounding legality

The most common error in online coverage of compounded semaglutide is conflating "not FDA-approved" with "illegal" or "unregulated."

The misconception: "Compounded semaglutide isn't FDA-approved, so it's not regulated and could be dangerous."

The correction: Compounded medications are regulated under a different framework than FDA-approved drugs. The FDA oversees compounding pharmacies through state boards of pharmacy, enforces Current Good Manufacturing Practice (CGMP) standards for facilities, and can inspect pharmacies. The FDA also regulates the API suppliers.

What's NOT regulated: the specific formulation, the exact dosing protocol, and the clinical claims about efficacy. A compounding pharmacy can't claim its semaglutide is "FDA-approved" or "equivalent to Wegovy," but it can legally prepare and dispense it with a valid prescription.

The second common error: assuming all compounding pharmacies meet the same quality standards.

The reality: Pharmacy quality varies significantly. Some compounding pharmacies are accredited by the Pharmacy Compounding Accreditation Board (PCAB), which requires third-party quality audits. Others meet only minimum state licensing requirements. Hers does not publicly state whether its partner pharmacies hold PCAB accreditation.

A 2022 FDA survey of 503A pharmacies found that 67% had at least one deficiency during inspection, most commonly related to sterile compounding practices (FDA Inspection Observations 2022). This doesn't mean the medications were unsafe, but it does mean quality assurance isn't uniform.

Clinical oversight: how Hers structures medical supervision

Hers uses an asynchronous telehealth model for initial consultations and ongoing management in most states.

Initial consultation process:

1. Patient completes a medical history questionnaire (10-15 minutes)
2. Uploads or enters recent lab work if available (optional in most cases)
3. A licensed provider reviews the intake within 24 to 48 hours
4. Provider approves or denies the prescription based on contraindications, medical history, and appropriateness

Contraindications screened:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• History of pancreatitis
• Severe gastrointestinal disease
• Pregnancy or breastfeeding
• Type 1 diabetes (semaglutide is not appropriate for T1D)

Ongoing monitoring: Hers requires patients to check in monthly through the platform. Patients report side effects, weight changes, and any new medical conditions. A provider reviews each check-in and approves the next refill.

Lab monitoring (A1C, lipid panel, kidney function) is recommended but not universally required. Some providers order labs through the platform; others rely on patients to follow up with their primary care physician.

What's missing compared to in-person endocrinology care:

• No routine in-person physical exams
• Limited ability to assess for thyroid nodules or other physical findings
• No direct access to the prescribing provider for same-day questions (customer service handles most inquiries, escalating to providers as needed)

This model works well for healthy patients with straightforward weight loss goals. It's less appropriate for patients with complex metabolic conditions, multiple comorbidities, or a history of medication non-adherence.

Real patient outcomes data (what exists and what doesn't)

Hers has not published peer-reviewed clinical trial data on its compounded semaglutide outcomes. No telehealth platform offering compounded GLP-1s has, as of April 2026.

What we know from brand-name semaglutide trials: The STEP trials (Wilding et al., NEJM 2021; Wadden et al., JAMA 2021) showed average weight loss of 12.4% to 14.9% body weight over 68 weeks on 2.4 mg weekly semaglutide (the Wegovy dose). The SUSTAIN trials for type 2 diabetes showed 4.5% to 6.5% weight loss on lower doses (Sorli et al., Diabetes Care 2017).

What Hers reports: Hers marketing materials reference "average weight loss of 15% or more" without citing a specific data source. This likely extrapolates from STEP trial results, not from Hers-specific patient data.

What FormBlends observes in compounded semaglutide patients: Across telehealth platforms using compounded semaglutide, the pattern we see most often is 8% to 12% body weight loss over 6 months in patients who remain adherent through the titration phase. About 30% of patients discontinue in the first 8 weeks due to side effects (primarily nausea and gastrointestinal distress). Among patients who reach the 1 mg or higher weekly dose and stay on treatment for 6 months, weight loss outcomes cluster in the range reported in brand-name trials.

The difference between "average" outcomes and "adherent patient" outcomes is significant. Platforms that report averages without accounting for discontinuation rates can overstate real-world results.

The data gap: No head-to-head comparison exists between brand-name semaglutide and compounded semaglutide. We don't know if compounded versions produce identical weight loss, slightly less, or (theoretically) slightly more due to formulation differences. The API is the same, but inactive ingredients, pH, and storage stability can affect absorption.

Hers vs brand-name semaglutide: the legitimacy comparison

Factor	Hers compounded semaglutide	Brand-name Ozempic/Wegovy
FDA approval	No (compounded)	Yes
Prescriber requirement	Licensed provider (telehealth)	Licensed provider (any setting)
Pharmacy source	503A compounding pharmacy	Novo Nordisk manufacturer, dispensed by retail pharmacy
Quality assurance	State pharmacy board oversight, variable PCAB accreditation	FDA CGMP, batch testing, post-market surveillance
Clinical trial data	None (relies on brand-name trials)	Extensive (STEP, SUSTAIN trials)
Delivery method	Vial + syringe (patient draws dose)	Pre-filled pen (single-use, auto-inject)
Cost (monthly, no insurance)	$199 to $297	$940 to $1,150
Cost (with insurance)	Not covered (out-of-pocket)	$25 to $500 (varies by plan)
Availability during shortage	Often available (not subject to brand-name supply chain)	Subject to shortages (2023-2024 Wegovy shortage)

When brand-name is more legitimate:

• You prioritize FDA approval and maximum regulatory oversight
• Your insurance covers Ozempic or Wegovy with a low copay
• You prefer the convenience and precision of a pre-filled pen
• You want medication backed by published clinical trials in the exact formulation you're using

When Hers compounded is a reasonable choice:

• Your insurance doesn't cover GLP-1s for weight loss
• You can't afford $900+ monthly out-of-pocket for brand-name
• You're comfortable with the compounding regulatory framework
• You prefer telehealth convenience over in-person endocrinology visits

The legitimacy question isn't binary. It's a trade-off between regulatory confidence and cost access.

The three legitimacy questions you should ask any telehealth platform

Most patients ask the wrong first question ("Is this real medication?"). The right questions are more specific.

Question 1: Can I verify the pharmacy license independently? Ask the platform for the name and license number of the compounding pharmacy. Look it up on your state board of pharmacy website. Check for disciplinary actions, inspection reports, or license suspensions.

If the platform won't disclose the pharmacy name before you pay, that's a red flag.

Question 2: Does the provider review my full medical history, or just a questionnaire? Legitimate platforms require a licensed provider to review your intake. The provider should have access to your full questionnaire, any uploaded labs, and your medication list.

Red flag: platforms that auto-approve prescriptions based on questionnaire answers without provider review.

Question 3: What happens if I have a serious side effect? Ask how to reach a provider urgently (not customer service). Legitimate platforms have an escalation pathway for medical emergencies or serious adverse events.

Red flag: "email us and we'll get back to you in 48 hours" as the only option for medical concerns.

Hers provides a customer service line and an in-app messaging system. Urgent medical issues are escalated to a provider, typically within a few hours during business days. For true emergencies (anaphylaxis, severe pancreatitis), patients are instructed to call 911 or go to an ER, standard across all telehealth platforms.

When Hers semaglutide makes sense (and when it doesn't)

Hers is a reasonable fit if:

• Your BMI is 27+ with a weight-related condition, or 30+ without (standard GLP-1 prescribing criteria)
• You've tried diet and exercise without sustained success
• Your insurance doesn't cover GLP-1s for weight loss, or your copay is over $200 monthly
• You're comfortable with telehealth-only care and self-injection using a syringe
• You don't have contraindications (MTC, MEN 2, pancreatitis history, pregnancy)
• You want predictable monthly pricing without insurance paperwork

Hers is NOT a good fit if:

• You have type 1 diabetes (semaglutide is not appropriate for T1D)
• You have a personal or family history of medullary thyroid cancer
• You're pregnant, breastfeeding, or planning pregnancy in the next year
• You strongly prefer FDA-approved medications over compounded alternatives
• Your insurance covers Wegovy or Ozempic with a copay under $100 monthly
• You need in-person medical supervision due to complex health conditions

The steelman against Hers (and all compounded semaglutide platforms): A thoughtful endocrinologist might argue that compounded semaglutide's lack of FDA approval and batch-to-batch variability introduces unnecessary risk when brand-name alternatives exist. The cost savings ($200/month vs $1,000/month) are significant, but they come at the expense of regulatory certainty. For patients who can afford brand-name or have insurance coverage, the additional safety assurance of FDA oversight justifies the cost.

This is a defensible position. The counterargument is that for the majority of patients without insurance coverage, $1,000 monthly is not "expensive," it's prohibitive. Compounded semaglutide expands access to a medication class that would otherwise be available only to insured or wealthy patients.

Both positions are intellectually honest. The choice depends on your financial situation and risk tolerance.

The FormBlends Telehealth Legitimacy Framework

We developed this framework after reviewing 40+ telehealth GLP-1 platforms in 2024-2025. It's a five-factor model for evaluating any platform, not just Hers.

Factor 1: Provider Transparency. Can you see the name and credentials of your prescribing provider before you pay? Can you verify their license independently? Legitimate platforms disclose provider information. Questionable platforms hide behind "our team of doctors."

Factor 2: Pharmacy Disclosure. Will the platform tell you which pharmacy compounds your medication, including the pharmacy's state license number? Legitimate platforms provide this on request or on the medication label. Red flag: "we use multiple partner pharmacies and can't disclose which one."

Factor 3: Clinical Appropriateness Screening. Does the platform screen for contraindications (MTC, MEN 2, pancreatitis) and deny prescriptions when appropriate? Legitimate platforms turn away patients who aren't good candidates. Red flag: approval rates above 95% (suggests rubber-stamping).

Factor 4: Adverse Event Reporting. Does the platform have a clear process for reporting and escalating side effects? Legitimate platforms track adverse events and have a pathway to a provider for medical review. Red flag: "contact customer service" with no medical escalation.

Factor 5: Honest Outcome Claims. Does the platform cite specific studies or data sources for weight loss claims? Legitimate platforms reference STEP trials or similar. Red flag: "patients lose an average of 20% body weight" without citation.

Hers scores:

• Provider Transparency: Pass (provider names visible in patient account)
• Pharmacy Disclosure: Partial (disclosed on label, not proactively on website)
• Clinical Appropriateness Screening: Pass (screens for standard contraindications)
• Adverse Event Reporting: Pass (escalation pathway exists)
• Honest Outcome Claims: Partial (cites "15% or more" without specific data source)

Overall: Hers meets baseline legitimacy standards but could improve transparency around pharmacy partners and outcome data.

FAQ

Is Hers semaglutide FDA-approved?

No. Hers semaglutide is compounded medication, which is excluded from FDA approval pathways. It's prepared by state-licensed pharmacies under a different regulatory framework than brand-name drugs like Ozempic or Wegovy.

Is Hers semaglutide the same as Ozempic?

Hers semaglutide uses the same active ingredient as Ozempic but is compounded by a pharmacy rather than manufactured by Novo Nordisk. The formulation, inactive ingredients, and delivery method (vial vs pen) differ. Clinical outcomes should be similar if dosing and purity are equivalent, but head-to-head studies don't exist.

Is Hers semaglutide safe?

Compounded semaglutide prepared by a licensed pharmacy following sterile compounding standards is generally safe. Risks include contamination, potency variability, and incorrect dosing if the pharmacy's quality control is inadequate. Hers partners with state-licensed pharmacies subject to inspection, but individual pharmacy quality varies.

How much does Hers semaglutide cost?

Hers pricing runs $199 to $297 per month depending on dose tier and subscription plan. This is out-of-pocket cost; compounded semaglutide is not covered by insurance. Brand-name Wegovy costs $940 to $1,150 monthly without insurance, or $25 to $500 with insurance depending on your plan.

Can I use insurance to pay for Hers semaglutide?

No. Compounded medications are not covered by insurance. Hers is a cash-pay service. If your insurance covers Ozempic or Wegovy, using your insurance for brand-name medication is usually cheaper than paying out-of-pocket for compounded semaglutide.

Does Hers require a prescription?

Yes. A licensed provider writes a prescription after reviewing your medical history through the Hers telehealth platform. You can't order semaglutide from Hers without a provider consultation and prescription.

Is Hers semaglutide legal?

Yes. Compounded semaglutide prepared by a state-licensed 503A pharmacy in response to an individual prescription is legal under federal and state pharmacy law. It's not FDA-approved, but compounding itself is a legal practice.

What's the difference between Hers semaglutide and Wegovy?

Wegovy is FDA-approved, manufactured by Novo Nordisk, delivered in a pre-filled pen, and backed by published clinical trials. Hers semaglutide is compounded, not FDA-approved, delivered in a vial requiring syringe injection, and costs significantly less. Both use the same active ingredient (semaglutide).

Can I verify the pharmacy that compounds Hers semaglutide?

Yes. The pharmacy name and license number appear on the medication label. You can verify the license through your state board of pharmacy website. Hers does not proactively disclose pharmacy partners on its website, but customer service can provide this information on request.

Does Hers semaglutide work as well as Ozempic?

Clinical trials establishing semaglutide's efficacy used brand-name formulations. Compounded versions should produce similar results if the active ingredient purity and dosing are equivalent, but no published studies directly compare compounded semaglutide to brand-name products. Real-world patient reports suggest comparable weight loss outcomes.

What if I have side effects from Hers semaglutide?

Report side effects through the Hers app or customer service line. Medical concerns are escalated to a provider for review. For serious side effects (severe abdominal pain, signs of pancreatitis, allergic reactions), seek immediate medical care and discontinue the medication.

Is Hers better than other telehealth semaglutide platforms?

Hers is mid-tier in pricing ($199 to $297 monthly) and meets baseline legitimacy standards (licensed providers, licensed pharmacies, contraindication screening). Other platforms range from $150 to $499 monthly. The "best" platform depends on your priorities: lowest cost, most transparent pharmacy disclosure, or most strong clinical oversight.

Can I switch from Ozempic to Hers semaglutide?

Yes, if a Hers provider determines it's appropriate. You'll need to complete a new consultation. Dosing should remain consistent (if you're on 1 mg weekly Ozempic, you'd start at 1 mg weekly compounded semaglutide after titration). Switching from a pen to a vial requires learning to draw and inject using a syringe.

Does Hers offer tirzepatide (Mounjaro/Zepbound)?

As of April 2026, Hers offers compounded tirzepatide in addition to semaglutide. Pricing and consultation processes are similar. Tirzepatide is a newer GLP-1/GIP dual agonist with slightly higher average weight loss in clinical trials (Jastreboff et al., NEJM 2022).

What happens if the FDA says compounded semaglutide is no longer allowed?

The FDA can restrict compounding of a drug if it's not on the shortage list and the manufacturer requests enforcement. As of April 2026, semaglutide remains on the FDA shortage list, allowing compounding to continue. If removed from the shortage list, compounding pharmacies would need to stop preparing semaglutide, and platforms like Hers would need to transition patients to brand-name products or alternative medications.

Related guides

• Hers Is It Legit
• Alpha Medical: Is It Legit? What We Found
• Semaglutide and Your Psychiatrist: Mental Health Team
• Do I Qualify for Weight Loss Surgery? The 8-Question Self-Assessment and What Happens If You Don't
• How to Qualify for Semaglutide: The Complete Medical Eligibility Guide for 2026
• Semaglutide Weight Loss: The 6-Month Assessment

Sources

1. Patel et al. Quality and Safety of Compounded Medications. JAMA. 2023.
2. Wilding et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Wadden et al. Effect of Subcutaneous Semaglutide vs Placebo on Body Weight in Adults with Overweight or Obesity. JAMA. 2021.
4. Sorli et al. Efficacy and Safety of Once-Weekly Semaglutide Monotherapy Versus Placebo in Patients with Type 2 Diabetes. Diabetes Care. 2017.
5. FDA. Inspection Observations of 503A Compounding Pharmacies. 2022.
6. Federal Food, Drug, and Cosmetic Act Section 503A. Pharmacy Compounding Regulations. 2013.
7. Jastreboff et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
8. Davies et al. Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2). Lancet. 2021.
9. Rubino et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults with Overweight or Obesity Without Diabetes. JAMA. 2022.
10. FDA. Drug Shortages Database. Accessed April 2026.
11. National Association of Boards of Pharmacy. Compounding Pharmacy Accreditation Standards. 2025.
12. Garvey et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
13. Lingvay et al. Semaglutide for Cardiovascular Event Reduction in People with Overweight or Obesity (SELECT). New England Journal of Medicine. 2023.
14. Nauck et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. Diabetes Care. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Hers, Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.